Crizotinib (PF-02341066)

Pfizer辉瑞授权目录号：S1068

Molecular Weight(MW): 450.34

Crizotinib (PF-02341066) 克唑替尼是一种有效的c-Met和ALK抑制剂，在细胞试验中IC50分别为11 nM 和 24 nM。它同时也是有效的ROS1抑制剂，其Ki值小于0.025 nM。

规格

价格

库存

购买数量

10mM/1mL In DMSO	RMB 1812.55	现货
5mg	RMB 900.49	现货
10mg	RMB 1372.81	现货
50mg	RMB 4681.47	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck该产品发表文献129篇：

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Cell, 2018, 174(4):856-869

PubMed: 30096312 ( click the link to review the publication )

Nature, 2016, 534(7609):647-51

PubMed: 27338794 ( click the link to review the publication )

J Clin Oncol, 2016, 34(8):794-802

PubMed: 26215952 ( click the link to review the publication )

Cancer Discov, 2015, 10.1158/2159-8290.CD-15-0913

PubMed: 26566875 ( click the link to review the publication )

Cancer Cell, 2015, 27(3):397-408

PubMed: 25759024 ( click the link to review the publication )

Cancer Cell, 2015, 27(4):533-46

PubMed: 25873175 ( click the link to review the publication )

Cancer Discov, 2014, 4(12):1398-405

PubMed: 25266736 ( click the link to review the publication )

Nat Med, 2013, 19(11):1469-1472

PubMed: 24162815 ( click the link to review the publication )

Nature, 2012, 487(7408):505-9

PubMed: 22763448 ( click the link to review the publication )

Nat Med, 2012, 18(6):883-91

PubMed: 22635005 ( click the link to review the publication )

Cell, 2012, 151(5):937-50

PubMed: 23178117 ( click the link to review the publication )

Nat Med, 2011, 17(9):1116-20

PubMed: 21822287 ( click the link to review the publication )

Int J Mol Sci, 215, 16(1):2174-86

PubMed: 25608652 ( click the link to review the publication )

Cancer Res, 2019, 79(3):546-556

PubMed: 30538120 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Oncogene, 2019, 38(11):1936-1950

PubMed: 30390071 ( click the link to review the publication )

EBioMedicine, 2019, 42:326-339

PubMed: 30879923 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(3):718-725

PubMed: 30755456 ( click the link to review the publication )

Biochem Pharmacol, 2019, 166:128-138

PubMed: 31078602 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz123

PubMed: 31132080 ( click the link to review the publication )

Invest New Drugs, 2019, 10.1007/s10637-019-00795-3

PubMed: 31124056 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):951-962

PubMed: 30309221 ( click the link to review the publication )
Transl Oncol, 2019, 12(1):116-121

PubMed: 30290287 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 511(2):260-265

PubMed: 30791979 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

Leukemia, 2018, 32(9):1994-2007

PubMed: 29588546 ( click the link to review the publication )

Cell Syst, 2018, 6(3):329-342

PubMed: 29550255 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2622-2632

PubMed: 30282811 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(5):931-942

PubMed: 29440449 ( click the link to review the publication )

Mol Pharm, 2018, 15(5):1892-1900

PubMed: 29595984 ( click the link to review the publication )

Cancer Gene Ther, 2018, 26(1-2):1-10

PubMed: 29925897 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(8):1541-1550

PubMed: 30210922 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Cancer Commun (Lond), 2018, 38(1):19

PubMed: 29764505 ( click the link to review the publication )

Cancer Res Treat, 2018, 50(2):599-613

PubMed: 28675026 ( click the link to review the publication )

Oncol Lett, 2018, 16(5):5992-5996

PubMed: 30333870 ( click the link to review the publication )

Oncolytic Virother, 2018, 7:107-116

PubMed: 30538967 ( click the link to review the publication )

J Thorac Oncol, 2017, S1556-0864(17)30365-9

PubMed: 28502721 ( click the link to review the publication )

Cell Rep, 2017, 21(11):3298-3309

PubMed: 29241554 ( click the link to review the publication )

Br J Cancer, 2017, 117(12):1787-1797

PubMed: 29024938 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2234-2245

PubMed: 28729401 ( click the link to review the publication )

Oncologist, 2017, 22(2):158-164

PubMed: 28167572 ( click the link to review the publication )

Am J Cancer Res, 2017, 7(2):203-217

PubMed: 28337371 ( click the link to review the publication )

Oncol Lett, 2017, 13(6):4085-4092

PubMed: 28599410 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51675-51687

PubMed: 28881678 ( click the link to review the publication )

Nat Commun, 2016, 7:10690

PubMed: 26891683 ( click the link to review the publication )
J Thorac Oncol, 2016, 11(8):1273-1281

PubMed: 27068398 ( click the link to review the publication )

J Pathol, 2016, 238(4):543-9

PubMed: 26606880 ( click the link to review the publication )

Oncoimmunology, 2016, 5(3):e1094598

PubMed: 27141355 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2453-2463

PubMed: 27748897 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2236-2244

PubMed: 27748834 ( click the link to review the publication )

Cellular Signalling, 2016, 19;28(6):652-662

PubMed: 27006333 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2016, 77(3):623-8

PubMed: 26849637 ( click the link to review the publication )

Vet Parasitol, 2016, 227:64-8

PubMed: 27523939 ( click the link to review the publication )

Int J Surg, 2016, 28:179-84

PubMed: 26957017 ( click the link to review the publication )

World J Clin Oncol, 2016, 7(6):425-432

PubMed: 28008383 ( click the link to review the publication )

Sci Rep, 2016, 10.1038/srep24817

PubMed: 27102549 ( click the link to review the publication )

Springerplus, 2016, 5:348

PubMed: 27057482 ( click the link to review the publication )

Sci Rep, 2016, 6:32992

PubMed: 27623107 ( click the link to review the publication )

Tumour Biol, 2016, 37(4):4373-82

PubMed: 26499783 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.16

PubMed: 25656847 ( click the link to review the publication )

Nat Commun, 2015, 6:7002

PubMed: 25926053 ( click the link to review the publication )

Cancer Res, 2015, 10.1158/0008-5472.CAN-15-0370

PubMed: 25952648 ( click the link to review the publication )

Radiother Oncol, 2015, 114(2):173-81

PubMed: ( click the link to review the publication )

Radiother Oncol, 2015, 114(2):173-81

PubMed: ( click the link to review the publication )

Cancer Sci, 2015, 106(3):244-52

PubMed: 25581823 ( click the link to review the publication )

Lung Cancer, 2015, 90(3):590-7

PubMed: 26547802 ( click the link to review the publication )

J Cell Physiol, 2015, 230(9):2281-98

PubMed: 25704960 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 285(1):51-60

PubMed: 25841593 ( click the link to review the publication )
Int J Oncol, 2015, 46(3):1025-30

PubMed: 25502629 ( click the link to review the publication )

Onco Targets Ther, 2015, 8:375-83

PubMed: 25678804 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 10.1016/j.bbrc.2015.02.114

PubMed: 25735977 ( click the link to review the publication )

Cell, 2015, 162(6):1271-85

PubMed: 26359985 ( click the link to review the publication )

J Thorac Oncol, 2014, 9(11):1638-46

PubMed: 25144242 ( click the link to review the publication )

J Thorac Oncol, 2014, 9(11):1638-46

PubMed: ( click the link to review the publication )

J Thorac Oncol, 2014, 9(6):775-83

PubMed: 24828661 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(18):4806-15

PubMed: 25052479 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(44):E4706-15

PubMed: 25331893 ( click the link to review the publication )

Elife, 2014, 10.7554/eLife.03751

PubMed: 25551293 ( click the link to review the publication )

Cancer Lett, 2014, 351(2):215-21

PubMed: 24887559 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(1):134-43

PubMed: 24170771 ( click the link to review the publication )

Mol Cancer Ther, 2014, 10.1158/1535-7163.MCT-14-0274

PubMed: 25349307 ( click the link to review the publication )

Mol Oncol, 2014, 9(1):260-9

PubMed: 25226813 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Cancer Sci, 2014, 105(5):528-36

PubMed: 24612061 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2014, 140(4):589-98

PubMed: 24509625 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2014, 74(5):1023-8

PubMed: 25205428 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

Biomed Res Int, 2014, 2014:764981

PubMed: 25057499 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.10.126

PubMed: ( click the link to review the publication )

Jpn J Clin Oncol, 2014, 44(10):963-8

PubMed: 25170107 ( click the link to review the publication )

Future Oncol, 2014, 10(2):211-7

PubMed: 24490607 ( click the link to review the publication )

Leuk Res, 2014, 38(4):503-8

PubMed: 24486291 ( click the link to review the publication )
Korean J Parasitol, 2014, 52(4):439-41

PubMed: 25246725 ( click the link to review the publication )

Oncotarget, 2014, 5(13):4920-8

PubMed: 24952482 ( click the link to review the publication )

Urol Oncol, 2014, 32(6):877-84

PubMed: 24929890 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Int J Cancer, 2013, 133(2):427-36

PubMed: 23335077 ( click the link to review the publication )

Int J Cancer, 2013, 132(2):E74-84

PubMed: 22948846 ( click the link to review the publication )

Br J Cancer, 2013, 109(12):3084-91

PubMed: 24149177 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

Mol Oncol, 2013, 7(6):1093-102

PubMed: 23993685 ( click the link to review the publication )

ACS Chem Biol, 2013, 9(3):777-84

PubMed: 24397822 ( click the link to review the publication )

J Am Heart Assoc, 2013, 2(6):e000376

PubMed: 24308935 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1640-6

PubMed: 24118504 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1618-25

PubMed: 24112719 ( click the link to review the publication )

Int J Cardiol, 2013, 168(4):3486-94

PubMed: 23680593 ( click the link to review the publication )

Mol Pharmacol, 2013, 83(4):882-93

PubMed: 23371912 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2013, 272(1):245-55

PubMed: 23707608 ( click the link to review the publication )

J Cell Biochem, 2013, 114(4):816-22

PubMed: 23060267 ( click the link to review the publication )

PLoS One, 2013, 8(12):e84700

PubMed: 24386407 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56010

PubMed: 23418494 ( click the link to review the publication )

Tumour Biol, 2013, 35(4):3229-35

PubMed: 24293393 ( click the link to review the publication )

Springerplus, 2013, 2:497

PubMed: 24102046 ( click the link to review the publication )

CELON PHARMA, 2013, 2013

PubMed: ( click the link to review the publication )

Br J Pharmacol, 2012, 166(5):1669-83

PubMed: 22233293 ( click the link to review the publication )

Neoplasia, 2012, 14(7):572-84

PubMed: 22904675 ( click the link to review the publication )
ACS Chem Biol, 2012, 7(8):1429-35

PubMed: 22625864 ( click the link to review the publication )

J Biol Chem, 2012, 287(18):14586-97

PubMed: 22418436 ( click the link to review the publication )

J Biol Chem, 2012, 287(47):39812-23

PubMed: 23024367 ( click the link to review the publication )

PLoS One, 2012, 7(2):e30820

PubMed: 22319590 ( click the link to review the publication )

Pediatr Blood Cancer, 2012, 17(23):7394-401

PubMed: 22488797 ( click the link to review the publication )

Clin Cancer Res, 2011, 59(3):440-7

PubMed: 21948233 ( click the link to review the publication )

Cancer Res, 2011, 71(15):5255-64

PubMed: 21697284 ( click the link to review the publication )

J Biomol Screen, 2011, 16(2):141-54

PubMed: 21297102 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

产品安全说明书

c-Met抑制剂选择性比较

生物活性

产品描述

靶点

ROS1 ^[6] (Cell-free assay)	c-Met ^[1] (A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)	ALK ^[1] (Karpas299 cells)
<0.025 nM(Ki)	11 nM	24 nM

体外研究

PF-2341066作用于mIMCD3小鼠和MDCK犬上皮细胞，作用于c-Met磷酸化作用时具有相似效果，IC50分别为5 nM 和20 nM。PF-2341066作用于表达c-Met ATP-结合位点突变型V1092I 或H1094R或 P-环突变 M1250T 的NIH3T3 细胞，具有相似的活性，且活力增高，IC50分别为19 nM,2 nM 和15 nM,而作用于表达野生型受体的NIH3T3 细胞时，IC50为13 nM。^[1] 相反, 观察到PF-2341066作用于表达c-Met活化环突变型Y1230C 和Y1235D的细胞时，与作用于野生型受体相比，效果发生显著改变，IC50分别为127 nM 和92 nM。PF-2341066 作用于分别表达内源性c-Met 突变体R988C和 T1010I 的NCI-H69 和HOP92 细胞，也有效抑制c-Met 磷酸化, IC50分别为13 nM 和16 nM。与作用于c-Met相比，PF-2341066作用于VEGFR2 和PDGFRβ RTKs, 选择性高1000多倍，作用于IRK和Lck选择性高250多倍，作用于Tie2, TrkA,和TrkB选择性高40到60倍。PF-2341066 作用于RON和 Axl RTKs时选择性为20到30倍。相反，PF-2341066 作用于表达ALK RTK 的核磷蛋白 (NPM)- 间变性淋巴瘤激酶(ALK) 致癌融合突变体和 KARPAS299人间变性大细胞淋巴瘤(ALCL)细胞系时具有相近的IC50值，为24 nM。PF-2341066抑制c-Met依赖的癌细胞的肿瘤表现型，和内皮细胞的血管生成表现型。PF-2341066抑制人GTL-16胃癌细胞生长，IC50为9.7 nM。PF-2341066诱导 GTL-16细胞凋亡，IC50 为8.4 nM。PF-2341066 抑制HGF刺激的人NCI-H441肺癌细胞迁移和入侵，IC50分别为11 nM 和6.1 nM。PF-2341066抑制 MDCK细胞散射，IC50为16 nM。PF-2341066 抑制HGF-刺激的c-Met磷酸化,细胞存活，和Matrigel入侵，IC50分别为11 nM, 14 nM和35 nM。此外, PF-2341066抑制纤维蛋白胶中的血清刺激的 HMVEC分支小管形成 (形成血管)。^[1] PF-2341066 作用于Karpas299 或SU-DHL-1 ALCL细胞，也有效抑制 NPM-ALK磷酸化，IC50 为24 nM。PF-2341066 有效抑制细胞增殖，伴随着使细胞周期停在G(1)-S期，且诱导 ALK阳性的 ALCL 细胞凋亡，IC50为30 nM, 但是作用于ALK阴性的淋巴瘤细胞则无效果。 ^[2] 此外, PF-2341066 抑制骨肉瘤的一些活动行为，及其肿瘤生长 (例如,增殖和存活)和转移 (例如，入侵和形成克隆)。^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
BAF3	NXnmOGpHS3m2b4TvfIlkKEG\|c3H5		M1T0NVQ5KGh?	NWXhOXA2TE2VTx?=	M1;URWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCDTFugSlEyPzSOIH31eIFvfCClb3X4dJJme3OrbnegSW1NPCC5aYToJGlEPTBib3[gNE43OiEQvF2=	NGXUbXozOTV5MkW4PS=>
BAF3	NI\qdG1EgXSxdH;4bYMhSXO\|YYm=		MWO0PEBp	MkKxSG1UVw>?	NEi3PYpEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSUZ\|IHPlcIx{KGW6cILld5NqdmdiQVzLJGwyOTl4TTDteZRidnRiY3;lfJBz\XO\|aX7nJGVOVDRid3n0bEBKSzVyIH;mJFIvOiEQvF2=	NEXjTnAzOTV5MkW4PS=>
BAF3	NIjKTWJEgXSxdH;4bYMhSXO\|YYm=		M{jydVQ5KGh?	MmjqSG1UVw>?	MYDDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochTU2OND3BUGshf2m2aDDJR\|UxKG:oIECuNlgh\|ryP	NXTRcIZ1OjF3N{K1PFk>
Kelly	NH[3OXhEgXSxdH;4bYMhSXO\|YYm=			MW\EUXNQ	NIj6emVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBM\WyueTDj[YxteyCneIDy[ZN{cW6pIFHMT{BHOTF5NFygcZV1[W62IIfpeIghUUN3MDDv[kAxNjR{IN88US=>	NF\6bGwzOTV5MkW4PS=>
SH-SY5Y	NXztbHFyS3m2b4TvfIlkKEG\|c3H5			NXv2d4FkTE2VTx?=	MVvDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTTE1UYTW\IHPlcIx{KGW6cILld5NqdmdiQVzLJGYyOTd2TDDteZRidnRid3n0bEBKSzVyIH;mJFAvPTNizszN	M3;1PVIyPTd{NUi5
SMS-KCN	MYnDfZRwfG:6aXOgRZN{[Xl?			MkPRSG1UVw>?	MYHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTUXMuU0OQIHPlcIx{KGW6cILld5NqdmdiQVzLJHIyOjd3UTDteZRidnRid3n0bEBKSzVyIH;mJFAvQTFizszN	MWqyNVU4OjV6OR?=
BAF3	MnLqR5l1d3SxeHnjJGF{e2G7		NWnxcY5vPDhiaB?=	MnXxSG1UVw>?	NIi4TlREgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSUZ\|IHPlcIx{KGW6cILld5NqdmdiVHXsMWFNUyC5aYToJGlEPTBib3[gNE4yQSEQvF2=	MoP4NlE2PzJ3OEm=
3T3	Mm\FSpVv[3Srb36gRZN{[Xl?		M1LseFEhcA>?	NXPZfmVXTE2VTx?=	NFXaN2xKdmirYnn0bY9vKG:oIGLPUkBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wPEDPxE1?	M4TGPVIyQDF{NEG0
3T3-E	M4KwZmZ2dmO2aX;uJGF{e2G7		M1jRUVEhcA>?	NXvwO\|B{TE2VTx?=	NHjZdmdKdmirYnn0bY9vKG:oIGTJSVIh[XO\|ZYPz[YQh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:\|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwNES4JO69VQ>?	M1jKNVIyQDF{NEG0
A549	MmXmT4lv[XOnIFHzd4F6		NUXZ[mt6OSCq	NYnyc\|V1TE2VTx?=	M4fWOWlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiYz3NSXQhc2mwYYPlJIV5eHKnc4Pl[EBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGhITi2rbnT1Z4VlKGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODB6IN88US=>	NEHC[GIzOThzMkSxOC=>
BAF3-BCL	NUPDTZFUTnWwY4Tpc44hSXO\|YYm=		NFnMNowyKGh?	NU\MXY9UTE2VTx?=	MnTYTY5pcWKrdHnvckBw\iCDQlygZZN{\XO\|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:\|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDFwMUW5JO69VQ>?	NYq4[HlLOjF6MUK0NVQ>
HEK293	MkjFSpVv[3Srb36gRZN{[Xl?		NWPoZ2M5OSCq	NEPu[olFVVOR	M1[wfmlvcGmkaYTpc44hd2ZiQWjMJIF{e2W\|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkK5OEDPxE1?	NELROY4zOThzMkSxOC=>
HEK293	NXHLXG5ZTnWwY4Tpc44hSXO\|YYm=		M{jTe\|EhcA>?	NXyzO3Q2TE2VTx?=	NWm0c41EUW6qaXLpeIlwdiCxZjDJVkBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMj64PFch\|ryP	M4XQN\|IyQDF{NEG0
Jurkat	MlLoSpVv[3Srb36gRZN{[Xl?		NGfSfXQyKGh?	Ml;xSG1UVw>?	NWriOoJYUW6qaXLpeIlwdiCxZjDMR2sh[XO\|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR\|UxKG:oIEKuO\|QyKM7:TR?=	MUOyNVgyOjRzNB?=
KARPAS299	MVPLbY5ie2ViQYPzZZk>		M3v6UlEhcA>?	NF3ITnhFVVOR	Mo[4TY5pcWKrdHnvckBw\iCDTFugZZN{\XO\|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:\|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEKg{txO	M4\ibVIyQDF{NEG0
PAE	NHmwVIJHfW6ldHnvckBCe3OjeR?=		M{Lme\|EhcA>?	MkX1SG1UVw>?	NWjGcIxkUW6qaXLpeIlwdiCxZjDUVmtDKGG\|c3Xzd4VlKGG\|IHfyc5d1cCCoYXP0c5IucW6mdXPl[EBifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlM6QSEQvF2=	M{j5WVIyQDF{NEG0
BAF3	M4nwWWZ2dmO2aX;uJGF{e2G7		NIPXXIwzNTNiZB?=	MV\EUXNQ	MWDJcohq[mm2aX;uJI9nKFSHTD3meZNm\CCrboP1cIlvKHKnY3XweI9zKGW6cILld5Nm\CC5aYToJGlEPTBib3[gNU43PDNizszN	NInjfGkzOzd2MkK1Ni=>
KARPAS299	NXTsVlNMS3m2b4TvfIlkKEG\|c3H5		MXyyMVMh\A>?	MUjEUXNQ	MXHJR\|UxRTBwME[0NkDPxE1?	MkHnNlM4PDJ{NUK=
EBC1	NF;RVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mli0O\|IhcA>?	MX\EUXNQ	Mn;NTWM2OD1yLkCyN{DPxE1?	MWWyN\|k6OzN{OB?=
HCT116	NIDxcnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NILNeGE4OiCq	NHTMc5RFVVOR	M2X2XGlEPTB;MUSuPFIh\|ryP	MU[yN\|k6OzN{OB?=
MCF7	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIPYVFQ4OiCq	NYHYUHA5TE2VTx?=	MnPaTWM2OD17LkW4JO69VQ>?	NEnxblczOzl7M{OyPC=>
MDA-MB-231	NYPrSodtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2fkd\|czKGh?	MnHQSG1UVw>?	MnOwTWM2OD1zMD64JO69VQ>?	NH6wO2szOzl7M{OyPC=>
MKN45	M1mwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHjlUYg4OiCq	Mo\XSG1UVw>?	M1;v[WlEPTB;MD6wNVMh\|ryP	MoXVNlM6QTN\|Mki=
NCI-H441	MkXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Ml3TO\|IhcA>?	NVrlSmJzTE2VTx?=	NI\mT\|VKSzVyPUG3MlI2KM7:TR?=	MoWwNlM6QTN\|Mki=
NCI-H661	M4f5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1zRVFczKGh?	M1;h[mROW09?	MnjlTWM2OD1zMT60O{DPxE1?	NGrFbWQzOzl7M{OyPC=>
SK-MEL-28	M4PyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUnzN\|NVPzJiaB?=	MnjBSG1UVw>?	M4TQeWlEPTB;MUCuPVch\|ryP	NIPqZ5IzOzl7M{OyPC=>
SKOV3	NWnNRYVJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWXiS5M{PzJiaB?=	NETCe3VFVVOR	NHrBO2RKSzVyPUGyMlg2KM7:TR?=	NY\Pe2d7OjN7OUOzNlg>
SNU5	NVLKXXhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{DsT\|czKGh?	Mn\hSG1UVw>?	MWXJR\|UxRTBwMEG2JO69VQ>?	MlSwNlM6QTN\|Mki=
NCI-H2228	M1PCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWC3NkBp	MU\EUXNQ	NX7tUoFwUW6qaXLpeIlwdiCxZjDBUGsu\nW\|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMUG4JO69VQ>?	NXrY[Hh[OjR2M{K5NFk>
NCI-H3122	MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Moe1O\|IhcA>?	MYTEUXNQ	NIK1WIJKdmirYnn0bY9vKG:oIFHMT{1nfXOrb36g[JJqfmWwIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5zMEig{txO	M3TTRlI1PDN{OUC5
NCI-H3122	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUXJ[oliPzJiaB?=	NILtUYxFVVOR	MlO0TY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25iaX6gbJVu[W5iTlPJMWg{OTJ{IHPlcIx{KGijcnLvdolv\yCDTFugS\|EzPjmDIH31eIFvfCC5aYToJGlEPTBib3[gNE43OjNizszN	NIizU4EzPDR\|MkmwPS=>
NCI-H3122	MmrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGe4Wnc4OiCq	M4LnTWROW09?	NGTxTnBKdmirYnn0bY9vKG:oIFHMT{1nfXOrb36g[JJqfmWwIHPlcIwheHKxbHnm[ZJifGmxbjDpckBpfW2jbjDOR2kuUDNzMkKgZ4VtdHNiaHHyZo9zcW6pIFHMT{BNOTF7Nl2gcZV1[W62IIfpeIghUUN3MDDv[kAxNjh\|ODFOwG0>	MmjjNlQ1OzJ7MEm=
NIH-3T3	NVLx[ZdrU2mwYYPlJGF{e2G7		NUW3VHRvOSCq	MXXEUXNQ	NFHLcIJKdmirYnn0bY9vKG:oIHj1cYFvKHerbHSgeJlx\SCHTVy0MYZ2e2WmIFHMT{BmgHC{ZYPz[YQh[XO\|ZYPz[YQh[XNicHjvd5Bpd3K7bHH0[YQhSUyNIHzleoVtKHerdHigTWM2OCCxZjCwMlA5KM7:TR?=	MmHSNlQ1OzJ7MEm=
NIH-3T3	MXLLbY5ie2ViQYPzZZk>		MWOxJIg>	MkLZSG1UVw>?	NIDiVHRKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGcyOjZ7QTDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLk[wOUDPxE1?	NFnK[XAzPDR\|MkmwPS=>
NIH-3T3	NH\kRlBMcW6jc3WgRZN{[Xl?		NHfie\|YyKGh?	M13PO2ROW09?	NH\1NHhKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJHMyOjB4WTDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLk[yOkDPxE1?	NIDuUXYzPDR\|MkmwPS=>
NIH-3T3	NVXsVpJlU2mwYYPlJGF{e2G7		NHnCOG0yKGh?	NH;iUXBFVVOR	M{TXemlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugUFEyQT[PIH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwOESzJO69VQ>?	NWiybWVLOjR2M{K5NFk>
NIH-3T3	MYrLbY5ie2ViQYPzZZk>		NF:xO4cyKGh?	NVT2OWtYTE2VTx?=	M{nlbmlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugUFEyPTKUIH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDFwMEK2JO69VQ>?	MnzMNlQ1OzJ7MEm=
BAF3	MmrSSpVv[3Srb36gRZN{[Xl?		MV63NkBp	M4DJe2ROW09?	M2ewbGlvcGmkaYTpc44hd2ZiTmDNM2FNUyC2cnHud4Zm[3SnZDDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIIfpeIghUUN3MDDv[kAxNjB3MTFOwG0>	NWiwPXpnOjR2Nki2N\|I>
BAF3	M4jOfGN6fG:2b4jpZ{BCe3OjeR?=		M2mwXVczKGh?	MkX4SG1UVw>?	NH3IVZJKSzVyPUCuPVgh\|ryP	MkDiNlQ1Pjh4M{K=
NIH-3T3	M2rIVWtqdmG\|ZTDBd5NigQ>?		NVzN[5Q5OSCq		M1zLTGlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugSlEyPzSOIH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwMU[1JO69VQ>?	M4CxNlI1QDF7MUG2
NIH-3T3	NEDDUlhMcW6jc3WgRZN{[Xl?		NHjOSnAyKGh?		NWTVS4NRUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BEOTF3NmmgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:\|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD60O\|gh\|ryP	MmDoNlQ5OTlzMU[=
NIH-3T3	MX;LbY5ie2ViQYPzZZk>		NEPYT5MyKGh?		NHOxWJhKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGcyOjB{UjDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iBzLkG0PEDPxE1?	MV[yOFgyQTFzNh?=
NIH-3T3	M2P3[WtqdmG\|ZTDBd5NigQ>?		M3PZWFEhcA>?		Ml74TY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzCxNVUyXGmwczDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iB\|LkCzPUDPxE1?	Mn[1NlQ5OTlzMU[=
KARPAS299	NWPHWGpCU2mwYYPlJGF{e2G7		MortPVAhdWmw	NWDMNmxITE2VTx?=	Mm\kTY5pcWKrdHnvckBw\iCQUF2t[pV{\WRiQVzLJJBpd3OyaH;yfYxifGmxbjDlfJBz\XO\|ZXSge4l1cCCLQ{WwJI9nKDBwMUGg{txO	NFLiU4szPDlyMEe1NC=>
MKN 45	M{PlR2tqdmG\|ZTDBd5NigQ>?		MmTJNUBp	MorMSG1UVw>?	NIDHR\|RKdmirYnn0bY9vKG:oIHOtUYV1KHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNkDPxE1?	NGTqV24zPDlyMEe1NC=>
A549	NIPZSppEgXSxdH;4bYMhSXO\|YYm=		M4DQXlQ5KGh?	M2nzWGROW09?	NULrWG97UUN3MDDv[kA1NjB6NDFOwG0>	NF32cHozPDlyMEizNC=>
NCI-H1975	NV7tOZk2S3m2b4TvfIlkKEG\|c3H5		MXS0PEBp	NXfmXJAzTE2VTx?=	M4DBdmlEPTBib3[gO{42PTFizszN	MX6yOFkxODh\|MB?=
NCI-H1993	MYTDfZRwfG:6aXOgRZN{[Xl?		M1raO\|Q5KGh?	MXLEUXNQ	M3\MNGlEPTBib3[gNE4xPjFizszN	NEPrPYczPDlyMEizNC=>
NCI-H1993	NHTEZYFCeG:2b4Ppd{BCe3OjeR?=	MV6xJO69VQ>?	MX[yOEBp	M{nsTmROW09?	NVH0OmdG\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppdy=>	NFrmboIzPDlyMEizNC=>
NIH-3T3	MYrDfZRwfG:6aXOgRZN{[Xl?		NXzqV5pOPDhiaB?=	NW\z[FlITE2VTx?=	MWTJR\|UxKG:oIECuN\|Y1KM7:TR?=	MmrtNlQ6ODB6M{C=
EBC1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkH6O\|IhcA>?	NULmR2prTE2VTx?=	Mn\TTWM2OCCxZjCwMlAxPjlizszN	Mn\BNlQ6ODB6M{G=
KARPAS299	NUD1SolJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NV;kdHJVPzJiaB?=	M374bWROW09?	MUXJR\|UxKG:oIECuNkDPxE1?	NFjMbVYzPDlyMEizNS=>
NB1	M1XodGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV[0XFRTUUN3ME25NU46QCCwTR?=	MX;TRW5ITVJ?
NCI-SNU-5	NE[1fIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2fkRWlEPTB;MUC1Mlc2KG6P	NHnoZ4VUSU6JRWK=
SR	NVLrZm9iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmLuTWM2OD1zMk[uN\|Ehdk1?	MkHhV2FPT0WU
SF539	NXnzWpdUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHKxPXhKSzVyPUKwOE4zPCCwTR?=	NYSweoU{W0GQR1XS
SU-DHL-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTN\|Nj64NkBvVQ>?	NUTmOmVSW0GQR1XS
SCC-3	MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TwdmlEPTB;M{W2Mlc3KG6P	MlnVV2FPT0WU
DEL	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTN4OT65JI5O	MWLTRW5ITVJ?
CTV-1	MmnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYizWXFIUUN3ME21PVYvPDhibl2=	NGrjcJJUSU6JRWK=
EM-2	M1e4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlX6TWM2OD14MEGuN\|Qhdk1?	MkTGV2FPT0WU
MHH-CALL-2	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;NNopKSzVyPU[4Nk42PyCwTR?=	Mnv0V2FPT0WU
KM12	MmPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrEWmNKSzVyPUewOk46KG6P	MnHvV2FPT0WU
KINGS-1	NE[0PIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYXoRVBMUUN3ME23OFkvPzVibl2=	NVnlXVBHW0GQR1XS
MEG-01	M4m1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTsTWM2OD16NUeuOlYhdk1?	MVzTRW5ITVJ?
BV-173	M3HZbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEnj[\|VKSzVyPUGuNFU6QTdizszN	NFLiNWxUSU6JRWK=
LAMA-84	M17CfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTFwM{iyPFIh\|ryP	NYnsfY1VW0GQR1XS
KARPAS-299	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXvNZdKSzVyPUGuOFA5PjFizszN	NYj4WIRpW0GQR1XS
K-562	M1r1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHf1d3dKSzVyPUGuO\|IzPjlizszN	NIHN[YRUSU6JRWK=
SK-LMS-1	NIexO21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWmwVYViUUN3ME2xMlc3QDZ5IN88US=>	NHe5[VRUSU6JRWK=
MOLT-16	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LWfmlEPTB;MT65OVU4PSEQvF2=	NWG1W3lDW0GQR1XS
CMK	NX\meYpLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLCTWM2OD1zLkm2NVU6KM7:TR?=	NEnNNmlUSU6JRWK=
ST486	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnjTTWM2OD1{LkSzNFc{KM7:TR?=	MXHTRW5ITVJ?
CI-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjxOopKSzVyPUKuOFk3PTlizszN	NFPPWo1USU6JRWK=
KP-N-RT-BM-1	MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojuTWM2OD1{LkewNVIzKM7:TR?=	NUXQV2xLW0GQR1XS
ALL-PO	M4rpVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTNwMUiyNFch\|ryP	NF7nUGZUSU6JRWK=
KS-1	MoLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTNwMkGyNlUh\|ryP	NVrNZWJ{W0GQR1XS
Becker	Mo\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3WwfGlEPTB;ND6yN\|k{KM7:TR?=	MnrYV2FPT0WU
GDM-1	NGDJRmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHkZlhtUUN3ME20MlI1PjF5IN88US=>	NI\vNZRUSU6JRWK=
BC-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIO4SHRKSzVyPUSuOFkzPzdizszN	MlPQV2FPT0WU
NB14	Mn7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1uzV2lEPTB;ND64N\|UzPCEQvF2=	NHK2XoFUSU6JRWK=
NOS-1	M3HvXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnmSGpGUUN3ME21MlM{QDd2IN88US=>	MVjTRW5ITVJ?
MZ1-PC	Mm\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHTKe4hKSzVyPUWuPFIyPTFizszN	Mk\vV2FPT0WU
A498	M1S1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LzN2lEPTB;Nj6wPFQ4OyEQvF2=	MWfTRW5ITVJ?
EW-16	M3jRb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nwemlEPTB;Nj6zO\|c4OyEQvF2=	M3jZeXNCVkeHUh?=
NALM-6	Mlv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\DWmlEPTB;Nj62PFM5PyEQvF2=	M1HCd3NCVkeHUh?=
EB-3	MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH:wdHFKSzVyPUeuNFczOzNizszN	MYnTRW5ITVJ?
697	M3LzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLGNHFKSzVyPUmuNlQ{OjlizszN	NIfVWodUSU6JRWK=
Ramos-2G6-4C10	M3Xte2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLVTWM2OD17LkW5PFQzKM7:TR?=	NX3TbmdWW0GQR1XS
KNS-81-FD	NGfHfolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MonxTWM2OD17Lk[5OlU{KM7:TR?=	M1qyRXNCVkeHUh?=
HUTU-80	M4m3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTlwN{S2OFIh\|ryP	NVy4c2I2W0GQR1XS
LS-411N	NYT2OlNvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELKZWRKSzVyPUGwMlA2PjdizszN	M1y5TXNCVkeHUh?=
RPMI-8402	MlTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGjPSYdKSzVyPUGwMlEyPiEQvF2=	NUDRW5pWW0GQR1XS
KU812	MkHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmrBTWM2OD1zMD6yPVkyKM7:TR?=	MULTRW5ITVJ?
EW-1	M4S0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkDzTWM2OD1zMD60OFI2KM7:TR?=	MVLTRW5ITVJ?
HC-1	NIHsPJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVTvR3BFUUN3ME2xNE41QDR2IN88US=>	MUXTRW5ITVJ?
NB69	NE[0Xo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\wdmlKSzVyPUGwMlUxPDNizszN	M3PPZnNCVkeHUh?=
MFH-ino	MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vvfGlEPTB;MUCuPFMxOyEQvF2=	NVy3fHUzW0GQR1XS
CCRF-CEM	MkPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlnOTWM2OD1zMT61PVch\|ryP	MoT5V2FPT0WU
SK-N-DZ	NGe0WIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHqPVRGUUN3ME2xNk4xPDN4IN88US=>	M17oSnNCVkeHUh?=
NCI-H720	Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTF{LkG3NFUh\|ryP	M1S5WnNCVkeHUh?=
HCC1187	NIX1[pNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGfPZWlKSzVyPUGyMlIxPDFizszN	NHzxN\|VUSU6JRWK=
IST-SL2	NXHjV3NiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTF{LkS4O\|Ih\|ryP	NGDMb2JUSU6JRWK=
KE-37	NE[xTYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLhTWM2OD1zMj63PVY3KM7:TR?=	M4TUdXNCVkeHUh?=
HCC1599	NXHxUYg2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYLLSJNqUUN3ME2xNk46ODZ7IN88US=>	NFHCWmJUSU6JRWK=
A4-Fuk	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHy0[mhKSzVyPUGyMlk2QDZizszN	Ml\qV2FPT0WU
NKM-1	MkK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTF\|LkK5NlUh\|ryP	M1\TfnNCVkeHUh?=
BE-13	NHH6[4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkHiTWM2OD1zMz63PVg6KM7:TR?=	NHPjPGNUSU6JRWK=
MV-4-11	NWPLUIdGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWT4flFbUUN3ME2xOE4xOzJ2IN88US=>	NIjmV2xUSU6JRWK=
OPM-2	NYrSNYtXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4fDUGlEPTB;MUSuOFA5PSEQvF2=	NXmxNYw{W0GQR1XS
KARPAS-422	MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFzmZ2NKSzVyPUG0MlUyOjZizszN	NHXiRWxUSU6JRWK=
RPMI-8226	NV3zeWJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{[0R2lEPTB;MUSuPFkyPSEQvF2=	MoTLV2FPT0WU
KARPAS-45	NVXrSYI1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDhTWM2OD1zNT63O\|E3KM7:TR?=	M3[2OXNCVkeHUh?=
SK-PN-DW	NFnBRmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7uTWM2OD1zNT64OlMyKM7:TR?=	MVTTRW5ITVJ?
LC-2	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHizXYpKSzVyPUG2MlE2ODZizszN	NF;vZ\|lUSU6JRWK=
NCI-H1648	NHXrUWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTF4LkK1OEDPxE1?	MkjwV2FPT0WU
RL95-2	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTF4LkO5O\|gh\|ryP	NYW0XXY4W0GQR1XS
KNS-42	M3;XSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17DTmlEPTB;MU[uO\|I4PCEQvF2=	NIPU[45USU6JRWK=
RPMI-6666	NFzrUGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;nd5VKSzVyPUG2MlkzOTFizszN	M2rvOXNCVkeHUh?=
SIG-M5	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXBPZNKSzVyPUG3MlE6ODNizszN	MUTTRW5ITVJ?
VA-ES-BJ	NFLUWm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITZ[oxKSzVyPUG3Mlc1PTFizszN	NHnYRpFUSU6JRWK=
MONO-MAC-6	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEG1eFdKSzVyPUG3Mlk{OTJizszN	NUXwfmRDW0GQR1XS
LAN-6	NGm5[WlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1fESmlEPTB;MUiuO\|U2PyEQvF2=	MoizV2FPT0WU
A388	M1XvfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIX6V45KSzVyPUG5MlMxPTlizszN	NF3aR5hUSU6JRWK=
SK-NEP-1	NFLzZ3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTJyLkKxN\|Ih\|ryP	NV\KT5FzW0GQR1XS
TE-10	Mlu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTJyLkWyNlEh\|ryP	NGrqTYxUSU6JRWK=
HL-60	MkK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkD4TWM2OD1{MD65NFk6KM7:TR?=	MlLmV2FPT0WU
MC116	NGPkenlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTJzLkeyNlEh\|ryP	MkPPV2FPT0WU
SW962	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjZNYVKSzVyPUKxMlc6OTVizszN	MWnTRW5ITVJ?
NOMO-1	M1;kOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\2TWM2OD1{Mj62OVY1KM7:TR?=	NIDJXW9USU6JRWK=
CTB-1	NGX1[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjpTGNKSzVyPUKyMlg3PzFizszN	NXi2WlZUW0GQR1XS
MRK-nu-1	NFP0[2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2DRcWlEPTB;MkKuPVA4PCEQvF2=	NYHwNFFIW0GQR1XS
GR-ST	M2qycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLCT4FKSzVyPUKzMlc3KM7:TR?=	NUfqOVBSW0GQR1XS
HH	NIHkVINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGW1NlBKSzVyPUK0MlAxOyEQvF2=	M3fjTnNCVkeHUh?=
NCI-H1963	Mm\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTJ2LkC3PFIh\|ryP	MWDTRW5ITVJ?
QIMR-WIL	NWiwZ4xlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PMO2lEPTB;MkSuPFc4OiEQvF2=	NVXCbVBxW0GQR1XS
CGTH-W-1	NYCwXoFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnP1TWM2OD1{NT6wO\|I{KM7:TR?=	M2jNd3NCVkeHUh?=
LP-1	Ml7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVjyVnBPUUN3ME2yOU43PTVzIN88US=>	Mnr6V2FPT0WU
NCI-H748	M3Tpcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HDOGlEPTB;Mk[uOVE{PyEQvF2=	MnOzV2FPT0WU
PF-382	M1fqeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XsXWlEPTB;MkeuNlIzOyEQvF2=	M4DsN3NCVkeHUh?=
ATN-1	Mon5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3LHTmlEPTB;MkeuN\|c{OiEQvF2=	M4fseXNCVkeHUh?=
L-540	NVnYRpE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWK4TYdLUUN3ME2yO{43PDV7IN88US=>	NFnkUplUSU6JRWK=
LXF-289	NVvX[4JiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkTITWM2OD1{Nz63OVE6KM7:TR?=	M4rl[3NCVkeHUh?=
LS-513	MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTJ6LkG4NFch\|ryP	M2nU[XNCVkeHUh?=
NCI-H1581	M4LIOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWjtOXJDUUN3ME2zNE4{QTd4IN88US=>	NFzGVlNUSU6JRWK=
ES6	NVnESXBqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGTDbm5KSzVyPUOwMlY5QTlizszN	M3;SVXNCVkeHUh?=
SW982	M1nSfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTNyLki1OlYh\|ryP	MoPxV2FPT0WU
DOHH-2	NVL3R3dFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIeyfI1KSzVyPUOxMlU5QTNizszN	NITlUZlUSU6JRWK=
DB	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTN\|Lkm0N\|Eh\|ryP	MUDTRW5ITVJ?
MPP-89	M3KxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M130U2lEPTB;M{SuNVc2PiEQvF2=	MYjTRW5ITVJ?
LB831-BLC	NHHIUVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTN2LkWxPFQh\|ryP	Ml7UV2FPT0WU
NB5	M1;zXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MorUTWM2OD1\|ND64OVM2KM7:TR?=	NGK2OXJUSU6JRWK=
GB-1	NVPPco9LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLQTWM2OD1\|NT6wOFY6KM7:TR?=	NEj3bnlUSU6JRWK=
TE-15	NVHpNpJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PSRWlEPTB;M{WuNlI{QCEQvF2=	NVfOUYd2W0GQR1XS
LC4-1	NUTaNnNjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33QVGlEPTB;M{WuN\|g1PyEQvF2=	MWDTRW5ITVJ?
NCI-H747	MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmXBTWM2OD1\|Nj6xN\|Y6KM7:TR?=	Mn7LV2FPT0WU
NTERA-S-cl-D1	Mk\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVrkRmtLUUN3ME2zPE44OzR5IN88US=>	MoK1V2FPT0WU
SK-MM-2	M1LLfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1r1WWlEPTB;NECuNVE1PiEQvF2=	M1ywSHNCVkeHUh?=
TGW	NHL4WnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTRzLkC1OlMh\|ryP	NETCU\|JUSU6JRWK=
ONS-76	NGDNR4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\lfGZKSzVyPUSyMlQ5QDNizszN	NFvIWphUSU6JRWK=
CPC-N	M33LO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWjB[mppUUN3ME20Nk46QTdzIN88US=>	MlLGV2FPT0WU
ES4	M{XTNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnYUIxuUUN3ME20OE41OTV\|IN88US=>	NHz1bYNUSU6JRWK=
Daudi	NHrDSVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7XTWM2OD12NT6wPFI4KM7:TR?=	NXrmcnBRW0GQR1XS
MOLT-4	NFfHRllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVLYXXBsUUN3ME20OU4xQDV\|IN88US=>	Mn7TV2FPT0WU
HT-144	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU[2XYdHUUN3ME20Ok44OjZizszN	M2SwSnNCVkeHUh?=
SW872	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFL4WWRKSzVyPUS4MlE6OzNizszN	M375eXNCVkeHUh?=
D-283MED	NGLtVo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGf2fHVKSzVyPUS4MlM2PDJizszN	MXTTRW5ITVJ?
NCI-H2126	NE\vbYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2nJdGlEPTB;NEiuPFQ4PiEQvF2=	MkXYV2FPT0WU
NCI-SNU-16	NFLqcmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13WPGlEPTB;NEmuNlE1OyEQvF2=	NHqzS45USU6JRWK=
CESS	Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmW0TWM2OD12OT61NFg5KM7:TR?=	M3PY[XNCVkeHUh?=
A101D	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGTMfYRKSzVyPUS5Mlk4OzZizszN	NIr1[5ZUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pALK / pAKT / pERK / pS6; PubMed: 24675041 Cancer Discov H3122 cells were treated with the indicated concentrations of crizotinib or ceritinib for 6 hours. Lysates were probed with antibodies directed against the specified proteins. pROS1 / ROS1; PubMed: 25351743 Clin Cancer Res Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins. pSTAT3 / STAT3; PubMed: 25351743 Clin Cancer Res Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins. PARP / cleaved caspase-3 / Bax / Bcl-2; PubMed: 25193856 Oncotarget The expression of PARP, cleaved caspase-3, Bax, and Bcl-2 were measured by western blotting after PANC-1 cells were treated with various concentrations of Crizotinib (0-10 μM) for 72 hr. p-c-Met / c-Met; PubMed: 25193856 Oncotarget Cancer cells with c-MET alterations were exposed to Crizotinib (10 μM) in the indicated times (SNU-5, MKN-45, and SNU-638: gastric cancer cells of c-MET amplification). p-mTOR; PubMed: 26384345 Oncotarget Immunoblotting for phospho- or total MET, STAT3, AKT, MTOR and ERK in SPC-A1 cells treated with crizotinib for 48 h.	24675041 25351743 25193856 26384345
Immunofluorescence	LC3 / lysosome; PubMed: 26384345 Oncotarget Cells were treated with DMSO or 4 μM crizotinib for 72 h before they were labeled with a fluorescent marker and imaged by fluorescence microscopy. Green: FITC-labeled LC3; Red: lyso-tracker-labeled lysosome; Blue: DAPI-labeled nucleus. SRC / Met; PubMed: 26517812 Oncotarget Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in (A) LN-18 and (B) U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively. α-tubulin; PubMed: 26517812 Oncotarget LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm. cytochrome c; PubMed: 25193856 Oncotarget PANC-1 pancreatic cancer cells were treated with Crizotinib (1 and 10 μM) for 6 hr and stained with anti-cytochrome c antibody, Mitotracker and DAPI. The immunostained cells were analyzed under an Olympus confocal laser scanning microscope with 400x magnification. Cytochrome c (green), mitotracker: red p-ALK; PubMed: 25193856 Oncotarget PANC-1 cells were also treated with various concentrations (0-10 μM) of Crizotinib and stained with p-ALK antibody and DAPI. The immunostained cells were analyzed under an Olympus confocal laser scanning microscope with 400x magnification.	26384345 26517812 25193856

体内研究

PF-2341066每天按50 mg/kg和75 mg/kg剂量处理GTL-16 模型, 引起大肿瘤 (体积大于600 mm³) 明显衰退，且按43天处理日程处理后，平均肿瘤体积降低60%。在另一项研究中, PF-2341066处理3个月以上，完全抑制GTL-16肿瘤生长，PF-2341066每天按50 mg/kg剂量处理小鼠，3个月后，只有1/12小鼠的肿瘤生长得到提高。PF-2341066每天按50 mg/kg剂量处理NCI-H441 NSCLC 模型处理周期为38天，观察到平均肿瘤体积降低43%。PF-2341066 每天按50 mg/kg剂量作用于 Caki-1 RCC模型，处理周期为33天，观察到平均肿瘤体积降低53%，且每种肿瘤体积降低至少30%。PF-2341066每天按 50 mg/kg剂量作用于 U87MG 恶性胶质瘤或PC-3前列腺癌移植瘤模型,几乎完全抑制肿瘤生长，在实验最后一天，抑制分别达97% 或84%。相反, PF-2341066每天按50 mg/kg剂量口服给药处理 MDA-MB-231 乳腺癌模型,或 DLD-1 结肠癌模型，不会显著抑制肿瘤生长。PF-2341066每天按12.5 mg/kg, 25 mg/kg, 和50 mg/kg剂量作用于 GTL-16 肿瘤，观察到CD31阳性内皮细胞显著降低，这种作用存在剂量依赖性，说明 MVD 受抑制，且具有相关的抗癌高效性，这种作用也存在剂量依赖性。PF-2341066 作用于GTL-16 和 U87MG 模型，显著降低人VEGFA 和IL-8血浆水平，这种作用存在剂量依赖性。PF-2341066口服处理GTL-16 肿瘤，观察到磷酸化的c-Met, Akt, Erk, PLCλ1,和 STAT5水平显著受抑制。^[1]PF-2341066 每天按100 mg/kg剂量口服处理携带Karpas299 ALCL 移植瘤的SCID Beige 小鼠，具有抗癌高效性，这种作用存在剂量依赖性，处理15天，所有肿瘤完全衰退。此外, PF-2341066抑制关键NPM-ALK信号调节器, 包括磷脂酶C-γ, 信号转导器，及转录因子3, 细胞外信号调节激酶, 和Akt的激活剂，这些与 NPM-ALK 磷酸化和功能受抑制相关。^[2] PF-2341066 抑制骨肉瘤的一些活动行为，及其肿瘤生长(例如, 增殖和存活)和转移 (例如，入侵和形成克隆)。PF-2341066口服饲喂裸鼠，抑制生长和相关的骨肉瘤裸鼠移植瘤的骨基质的形成。^[3] PF-2341066 按50 mg/kg 剂量处理 c-MET-扩增的GTL-16移植瘤，引起肿瘤衰退，这与¹⁸F-FDG 摄取的缓慢降低相关，且降低葡糖糖转运蛋白 1, GLUT-1的表达。^[4]

激酶实验： ^[1]	+ 展开生化激酶实验: 使用连续耦合的分光光度测定c-Met催化活性，通过分析NADH消耗率而测定c-Met诱导的ADP产量，这种作用具有时间依赖性。在 340 nm处使用分光光度法在指定时间点测定吸光值的降低而计算NADH的消耗量。为了测定K_i值, 在含实验试剂的实验孔中加入不同浓度PF-2341066，然后在37^oC下温育10分钟。加入c-Met酶开始进行实验反应。
细胞实验： ^[1]	+ 展开 Cell lines: GTL-16胃癌细胞和T47D乳腺癌细胞 Concentrations: 0 nM-256 nM Incubation Time: 1小时 Method: GTL-16胃癌细胞和T47D乳腺癌细胞接种在96孔板上，孔中含培养基，培养基中含10% 胎牛血清(FBS)，然后转移到无血清培养基中[含0.04%牛血清蛋白(BSA)]，处理 24小时。在调查配体依赖的RTK 磷酸化实验中，加入相应的生长因子，处理20分钟。细胞和 PF-2341066和/或适当配体在指定时间温育1小时，然后使用含 1 mmol/L Na₃VO₄的HBSS冲洗细胞一次,然后从细胞中获得蛋白裂解物。随后,通过夹心酶联免疫吸附试验法使用特定的捕获抗体在96孔板上测定选定蛋白激酶的磷酸化，使用特点检测抗体测定磷酸化的酪氨酸残基。抗体包被的实验板(a) 在蛋白裂解物存在时，在4^oC下过夜;(b)在溶于PBS的1% Tween-20 中冲洗7次;(c)在辣根过氧化物酶标记的抗总磷酸（PY-20）抗体（1:500）中温育20分钟;(d) 再次冲洗7次;(e)在3,3^′,5,5^′-四甲基联苯胺过氧化物酶底物中温育，开始显示反应，加入0.09 N H₂SO₄终止反应; (f)在450 nm 处使用分光光度计测定吸光度。 (Only for Reference)
动物实验： ^[1]	+ 展开 Animal Models: 携带NCI-H441,或DLD-1,或MDA-MB-231的雌性和雄性nu/nu小鼠 Formulation: -- Dosages: 12.5 mg/kg/day, 25 mg/kg/day, 和50 mg/kg/day Administration: 口服处理 (Only for Reference)

参考文献

+ 展开

溶解度 (25°C)

体外	DMSO	9 mg/mL (19.98 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+30% PEG 300+dd H2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Crizotinib (PF-02341066) SDF

分子量	450.34
化学式	C₂₁H₂₂Cl₂FN₅O
CAS号	877399-52-5
储存条件	3 years -20°C powder
储存条件	2 years -80°C in solvent
别名	N/A

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on )

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03439215	Recruiting	Carcinoma Non-Small-Cell Lung	Fondazione Ricerca Traslazionale\|Clinical Research Technology S.r.l.	June 13 2017	Phase 2
NCT02946216	Unknown status	Non-small Cell Lung Cancer Stage III\|Non-Small-Cell Lung Cancer Metastatic\|Adenocarcinoma of Lung\|EGFR Wildtype	First People''s Hospital of Hangzhou	November 2016	--
NCT02511184	Terminated	ALK-positive Advanced NSCLC	Pfizer\|Merck Sharp & Dohme Corp.	October 2015	Phase 1
NCT02419287	Recruiting	Anaplastic Large Cell Lymphoma ALK-Positive	University of Milano Bicocca	April 2015	Phase 2
NCT02499614	Unknown status	Carcinoma Non-Small-Cell Lung	Fondazione Ricerca Traslazionale	December 2014	Phase 2
NCT02510001	Active not recruiting	Solid Tumor\|Colorectal Cancer	University of Oxford\|Queen''s University Belfast\|Oxford University Hospitals NHS Trust\|Velindre NHS Trust\|University Hospital Antwerp\|Hospital Vall d''Hebron\|Saint Antoine University Hospital\|European Georges Pompidou Hospital\|Pfizer\|University of Turin Italy\|Belfast Health and Social Care Trust\|Beaumont Hospital\|European Commission\|Array BioPharma\|University of Paris 5 - Rene Descartes	November 2014	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?
回答：
Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

选择性强的c-Met抑制剂

PF-04217903 : C-Met-selective, IC50=4.8 nM.
活性最高的c-Met抑制剂

INCB28060 : C-Met, IC50=0.13 nM.
用于临床的c-Met抑制剂

Tivantinib (ARQ 197) : Phase III for Hepatocellular Carcinoma.
最新的c-Met抑制剂

EMD 1214063 ^New : Potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer.

研究领域

产品类型

Crizotinib (PF-02341066)

客户使用Selleck该产品发表文献129篇：

产品安全说明书

c-Met抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Crizotinib (PF-02341066) SDF

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on )

技术支持

常见问题及建议解决方法

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

相关c-Met产品